Pleomorphic lobular carcinoma in situ: Current evidence and a systemic review (Review)

Wazir,Umar; Wazir,Ali; Wells,Clive; Mokbel,Kefah

doi:10.3892/ol.2016.5331

Pleomorphic lobular carcinoma in situ: Current evidence and a systemic review (Review)

Authors:
- Umar Wazir
- Ali Wazir
- Clive Wells
- Kefah Mokbel
View Affiliations

Affiliations: Department of Oncoplastic Surgery and Surgical Oncology, The London Breast Institute, Princess Grace Hospital, London, UK, Department of Internal Medicine, Albany Medical Center, Albany, NY, USA
Published online on: November 1, 2016 https://doi.org/10.3892/ol.2016.5331
Pages: 4863-4868
Copyright: © Wazir et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pleomorphic lobular carcinoma in situ (PLCIS) has only recently been identified as a distinct pathological entity within classic lobular carcinoma in situ (CLCIS). As such, there is currently no consensus among clinicians regarding the optimal treatment of this disease. The present study determined the risk of concomitant invasive disease and ductal carcinoma in situ (DCIS) if PLCIS is observed on core needle biopsy (CNB) and collated the evidence regarding the risk of recurrence in relation to surgical margins and adjuvant therapy. In addition, the pertinent literature available through MedLine, PubMed, the WHO Clinical Trials Registry Platform and Google Scholar using appropriate keywords was reviewed. The pooled results of studies in the literature demonstrated a concomitant presence of invasive disease of 40%, and 15% for DCIS. The studies that examined recurrence rates indicated that the risk is reduced with ample resection margins (>2 mm) and adjuvant radiotherapy. However, recent studies raise concerns regarding breast conservation when pursuing clear margins. No level 1 evidence from prospective studies, randomized controlled trials (RCTs), or meta-analyses based on such RCTs was identified. This is a clinical issue that warrants investigation in appropriately powered well designed prospective studies for a satisfactory resolution of all concerns.

View Figures

View References

1	Frost AR, Tsangaris TN and Silverberg SG: Pleomorphic lobular carcinoma in situ. Pathology Case Reviews. 1:27–31. 1996. View Article : Google Scholar
2	Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V and Ollila DW: Breast surgeon's survey: No consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 19:116–118. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hussain M and Cunnick GH: Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast-a review. Eur J Surg Oncol. 37:279–289. 2011. View Article : Google Scholar : PubMed/NCBI
4	Pieri A, Harvey J and Bundred N: Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? World J Clin Oncol. 5:546–553. 2014. View Article : Google Scholar : PubMed/NCBI
5	Haagensen CD, Lane N, Lattes R and Bodian C: Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 42:737–769. 1978. View Article : Google Scholar : PubMed/NCBI
6	Ciocca RM, Li T, Freedman GM and Morrow M: Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol. 15:2263–2271. 2008. View Article : Google Scholar : PubMed/NCBI
7	Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F and Aref A: Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: Analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 23:5534–5541. 2005. View Article : Google Scholar : PubMed/NCBI
8	Aulmann S, Penzel R, Longerich T, Funke B, Schirmacher P and Sinn HP: Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat. 107:331–335. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bagaria SP, Shamonki J, Kinnaird M, Ray PS and Giuliano AE: The florid subtype of lobular carcinoma in situ: Marker or precursor for invasive lobular carcinoma? Ann Surg Oncol. 18:1845–1851. 2011. View Article : Google Scholar : PubMed/NCBI
10	Lien HC, Chen YL, Juang YL and Jeng YM: Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. Breast Cancer Res Treat. 150:447–455. 2015. View Article : Google Scholar : PubMed/NCBI
11	Green AR, Young P, Krivinskas S, Rakha EA, Paish E Claire, Powe DG and Ellis IO: The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. Histopathology. 54:419–427. 2009. View Article : Google Scholar : PubMed/NCBI
12	Sneige N, Wang J, Baker BA, Krishnamurthy S and Middleton LP: Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: A report of 24 cases. Mod Pathol. 15:1044–1050. 2002. View Article : Google Scholar : PubMed/NCBI
13	Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, Fitzgibbons PL, Jacobs TW, MacGrogan G, Peterse H, et al: Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 33:1683–1694. 2009. View Article : Google Scholar : PubMed/NCBI
14	Palacios J, Sarrio D, Garcia-Macias MC, Bryant B, Sobel ME and Merino MJ: Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol. 16:674–678. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sapino A, Frigerio A, Peterse JL, Arisio R, Coluccia C and Bussolati G: Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch. 436:421–430. 2000. View Article : Google Scholar : PubMed/NCBI
16	Fadare O, Dadmanesh F, Alvarado-Cabrero I, Snyder R, Mitchell J Stephen, Tot T, Wang SA, Ghofrani M, Eusebi V, Martel M and Tavassoli FA: Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases. Am J Surg Pathol. 30:1445–1453. 2006. View Article : Google Scholar : PubMed/NCBI
17	Carder PJ, Shaaban A, Alizadeh Y, Kumarasuwamy V, Liston JC and Sharma N: Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): Risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology. 57:472–478. 2010. View Article : Google Scholar : PubMed/NCBI
18	Chivukula M, Haynik DM, Brufsky A, Carter G and Dabbs DJ: Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: Clinical significance and immunoprofile. Am J Surg Pathol. 32:1721–1726. 2008. View Article : Google Scholar : PubMed/NCBI
19	Fasola CE, Jensen KC and Horst KC: Local regional recurrence among patients with pleomorphic lobular carcinoma in situ: Is there a role for radiation therapy? International Journal of Radiation OncologyBiologyPhysics. 84:S2382012. View Article : Google Scholar
20	Morris K, Howe M, Kirwan C and Harvey J: Clinical and phenotypic characteristics of core biopsy diagnosed pleomorphic lobular carcinoma-in-situ in a UK population (PLCIS). European Journal of Surgical Oncology (EJSO). 39:4842013. View Article : Google Scholar
21	Niell B, Specht M, Gerade B and Rafferty E: Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol. 199:929–935. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lavoué V, Graesslin O, Classe JM, Fondrinier E, Angibeau H and Levêque J: Management of lobular neoplasia diagnosed by core needle biopsy: Study of 52 biopsies with follow-up surgical excision. Breast. 16:533–539. 2007. View Article : Google Scholar : PubMed/NCBI
23	Georgian-Smith D and Lawton TJ: Calcifications of lobular carcinoma in situ of the breast: Radiologic-pathologic correlation. AJR Am J Roentgenol. 176:1255–1259. 2001. View Article : Google Scholar : PubMed/NCBI
24	Mahoney MC, Robinson-Smith TM and Shaughnessy EA: Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: Correlation with surgical excisional biopsy and mammographic follow-up. AJR Am J Roentgenol. 187:949–954. 2006. View Article : Google Scholar : PubMed/NCBI
25	Purdie CA, McLean D, Stormonth E, Macaskill EJ, McCullough JB, Edwards SL, Brown DC and Jordan LB: Management of in situ lobular neoplasia detected on needle core biopsy of breast. J Clin Pathol. 63:987–993. 2010. View Article : Google Scholar : PubMed/NCBI
26	Downs-Kelly E, Bell D, Perkins GH, Sneige N and Middleton LP: Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 135:737–743. 2011.PubMed/NCBI
27	Khoury T, Karabakhtsian RG, Mattson D, Yan L, Syriac S, Habib F, Liu S and Desouki MM: Pleomorphic lobular carcinoma in situ of the breast: Clinicopathological review of 47 cases. Histopathology. 64:981–993. 2014. View Article : Google Scholar : PubMed/NCBI
28	Flanagan MR, Rendi MH, Calhoun KE, Anderson BO and Javid SH: Pleomorphic lobular carcinoma in situ: Radiologic-pathologic features and clinical management. Ann Surg Oncol. 22:4263–4269. 2015. View Article : Google Scholar : PubMed/NCBI
29	N.C.C.N. guidelines, . Breast cancer. National Comprehensive Cancer Network; Fort Washington PA, USA: 2015, http://www.nccn.org/patients/guidelines/stage_0_breast/index.htmlAccessed, July 2015.
30	Guidelines for pathology reporting in breast disease, . NHS Cancer Screening Programmes & Royal College of Pathologists. South Sheffield, UK: 2005, http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58.htmlAccessed, July 2015.